Skip to content

    Lung Cancer Health Center

    Font Size
    A
    A
    A

    Lung Cancer Drug May Improve Survival

    Patients Taking Tarceva in Study Had Already Failed Chemo at Least Once
    By
    WebMD Health News

    July 13, 2005 -- Researchers report that a lung cancer drug called Tarceva may extend patients' lives with advanced non-small cell lung cancer.

    Lung cancer is the leading cause of cancer deaths in North America, write the researchers in The New England Journal of Medicine.

    Most lung cancers (nearly 80%) are non-small cell lung cancers, states a University of Toronto news release.

    Tarceva "can prolong survival in patients with non-small cell lung cancer after first-line or second-line chemotherapy," write the researchers. The medication targets a protein found on some cancer cells that helps non-small cell cancers grow.

    Tarceva, a pill, is approved as a treatment for patients whose lung cancer has continued to progress despite other treatments, including at least one prior chemotherapy treatment.

    Researcher's View

    "This drug offers a new treatment option to patients at a time in their disease when they have no other options," says Frances Shepherd, MD, in a news release.

    "Not only does [Tarceva] help them live longer, but it also improves their physical function, their quality of life, and it improves the symptoms of cough, shortness of breath, and pain," she continues.

    Shepherd is the Scott Taylor Chair in Lung Cancer Research and a medical oncologist at Toronto's Princess Margaret Hospital. She is also a professor of medicine at the University of Toronto.

    Improved Survival

    Shepherd's study included 731 people from around the world.

    All patients had non-small cell lung cancer that had spread locally or to more distant organs. They had already failed treatment with chemotherapy once or twice.

    The researchers gave Tarceva to 488 of the patients. The other 243 patients got a placebo.

    Average overall survival was 6.7 months with Tarceva and 4.7 months with the placebo, the researchers report.

    The disease did not progress for an average of 2.2 months with Tarceva and 1.8 months with the placebo.

    Tarceva's Target

    Tarceva targets epidermal growth factor receptors (EGFR), which play a role in cancer cell growth.

    "Since EGFR is often found in non-small cell lung cancer cells, it has been the focus of efforts to develop new agents that target the EGFR pathway," write Shepherd and colleagues.

    Today on WebMD

    Xray analysis
    Do you know the myths from the facts?
    chest x-ray
    Get to know them.
     
    woman taking pills
    Tips to managing them.
    Lung cancer xray
    See it in pictures, plus read the facts.
     
    Lung Cancer Risks Myths and Facts
    SLIDESHOW
    Woman getting ct scan
    Article
     
    Improving Lung Cancer Survival Targeted Therapy
    VIDEO
    cancer fighting foods
    Article
     
    Lung Cancer Surprising Differences Between Sexes
    VIDEO
    Pets Improve Your Health
    SLIDESHOW
     
    Vitamin D
    SLIDESHOW
    Lung Cancer Surgery Options
    VIDEO